JNJ

234.09

+1.8%↑

ISRG

495

-0.8%↓

ABT

107.61

-1.84%↓

RDY

13.71

+4.74%↑

NEOG

10.62

+4.63%↑

JNJ

234.09

+1.8%↑

ISRG

495

-0.8%↓

ABT

107.61

-1.84%↓

RDY

13.71

+4.74%↑

NEOG

10.62

+4.63%↑

JNJ

234.09

+1.8%↑

ISRG

495

-0.8%↓

ABT

107.61

-1.84%↓

RDY

13.71

+4.74%↑

NEOG

10.62

+4.63%↑

JNJ

234.09

+1.8%↑

ISRG

495

-0.8%↓

ABT

107.61

-1.84%↓

RDY

13.71

+4.74%↑

NEOG

10.62

+4.63%↑

JNJ

234.09

+1.8%↑

ISRG

495

-0.8%↓

ABT

107.61

-1.84%↓

RDY

13.71

+4.74%↑

NEOG

10.62

+4.63%↑

Home・Aandelen Lijst・Day One Biopharmaceuticals Inc

Day One Biopharmaceuticals Inc

Open

SectorGezondheidszorg

11.36 -0.7

Buy Sell

Overzicht

Wijziging aandelenprijs

24u

Huidig

Min

11.23

Max

11.78

Belangrijke statistieken
By Trading Economics
Inkomsten	11M -20M
Verkoop	5.9M 40M
Winstmarge	-49.569
Werknemers	184
EBITDA	16M -19M

Aanbevelingen
By TipRanks
Aanbevelingen	Strong Buy
12 Maanden Prognose	+99.73% upside

Dividenden
By Dow Jones
Volgende Winsten	24 feb 2026

Marktinformatie
By TradingEconomics
Marktkapitalisatie	486M 1.2B
Vorige openingsprijs	12.06
Vorige sluitingsprijs	11.36

Nieuwssentiment

By Acuity

50%

147 / 352 Rangschikking in Healthcare

Technische score

By Trading Central

Vertrouwen

Very Strong Bearish Evidence

6.26 / 7.47 Steun & Weerstand

Day One Biopharmaceuticals Inc Grafiek

Eerdere prestaties zijn geen betrouwbare indicator voor toekomstige resultaten.

Gerelateerd nieuws

2 feb 2026, 23:52 UTC

Acquisities, Fusies, Overnames

Elliott Management Doesn't Plan to Tender Its Shares at the Current Terms

2 feb 2026, 23:52 UTC

Acquisities, Fusies, Overnames

Elliott Management: Toyota Fudosan Revised Tender Offer for Toyota Industries 'Very Significantly Undervalues' Company

2 feb 2026, 23:48 UTC

Marktinformatie

Nikkei May Rise on Signs of U.S. Economic Strength -- Market Talk

2 feb 2026, 23:38 UTC

Marktinformatie

Gold Rises on Likely Technical Recovery, Dip-Buying Interest -- Market Talk

2 feb 2026, 23:28 UTC

Marktinformatie

SpaceX, xAI Deal Further Consolidates Musk's Businesses -- Market Talk

2 feb 2026, 23:23 UTC

Winsten

Palantir Achieves Another Revenue Record With $1.41 Billion Quarter -- 2nd Update

2 feb 2026, 22:57 UTC

Winsten

Palantir Reports Strong Earnings. The Stock Is Rising. -- Barrons.com

2 feb 2026, 22:22 UTC

Acquisities, Fusies, Overnames

What the Blockbuster SpaceX--xAI Merger Can Mean for Tesla Stock -- Barrons.com

2 feb 2026, 22:08 UTC

Marktinformatie

Australian Inflation Woes Rooted In Excess Govt Spending -- Market Talk

2 feb 2026, 21:51 UTC

Winsten

Palantir Reports Strong Earnings. The Stock Is Rising. -- Barrons.com

2 feb 2026, 21:50 UTC

Marktinformatie

Basic Materials Roundup: Market Talk

2 feb 2026, 21:49 UTC

Winsten

Disney's Streaming Profit Surges as CEO Decision Approaches -- 5th Update

2 feb 2026, 21:39 UTC

Winsten

Palantir Reports Strong Earnings. The Stock Is Rising. -- Barrons.com

2 feb 2026, 21:36 UTC

Winsten

Palantir Achieves Another Revenue Record With $1.41 Billion Quarter -- Update

2 feb 2026, 21:34 UTC

Winsten

Palantir Reports Strong Earnings. The Stock Is Rising. -- Barrons.com

2 feb 2026, 21:28 UTC

Acquisities, Fusies, Overnames

What a SpaceX--xAI Merger Could Mean for Tesla Stock -- Barrons.com

2 feb 2026, 21:23 UTC

Winsten

BYD, Chinese EV Stock Plunge On Weak Data. What That Means for Tesla Stock. -- Barrons.com

2 feb 2026, 21:19 UTC

Winsten

Palantir Technologies: U.S. Commercial Business Growing at 'Astonishing' Rate, Generating $507 Million Last Quarter, 137% Increase Over the Same Period the Year Before >PLTR

2 feb 2026, 21:17 UTC

Winsten

Palantir Achieves Another Revenue Record With $1.41 Billion Quarter -- WSJ

2 feb 2026, 21:17 UTC

Winsten

Palantir Reports Strong Earnings. The Stock Is Rising. -- Barrons.com

2 feb 2026, 21:10 UTC

Winsten

Palantir Reports Strong Earnings. The Stock Is Rising. -- Barrons.com

2 feb 2026, 21:08 UTC

Winsten

Palantir Technologies: Rule of 40 Score Is Now 127% >PLTR

2 feb 2026, 21:07 UTC

Winsten

Palantir Technologies: Sees 2026 U.S. Comml Rev in Excess of $3.144B, Representing Growth Rate of at Least 115% >PLTR

2 feb 2026, 21:05 UTC

Winsten

Palantir Technologies 4Q Net $608.7M >PLTR

2 feb 2026, 21:05 UTC

Winsten

Palantir Technologies 4Q Rev $1.41B >PLTR

2 feb 2026, 21:05 UTC

Winsten

Palantir Technologies Sees 1Q Rev $1.53B-$1.54B >PLTR

2 feb 2026, 21:05 UTC

Winsten

Palantir Technologies Sees FY Rev $7.18B-$7.2B >PLTR

2 feb 2026, 21:05 UTC

Winsten

Palantir Technologies 4Q Adj EPS 25c >PLTR

2 feb 2026, 21:05 UTC

Winsten

Palantir Technologies 4Q EPS 24c >PLTR

2 feb 2026, 20:40 UTC

Marktinformatie

Treasury Yields, Dollar Rise Amid Signs of Resilient U.S. Economy -- Market Talk

Peer Vergelijking

Prijswijziging

Day One Biopharmaceuticals Inc Prognose

Koersdoel

By TipRanks

99.73% opwaarts potentieel

12 Maanden Prognose

Gemiddelde 22.29 USD 99.73%

Hoogste 29 USD

Laagste 16 USD

Gebaseerd op 9 Wall Street-analisten die 12-maands prijsdoelen bieden voor Day One Biopharmaceuticals Inc - Dist. in de afgelopen 3 maanden.

Beoordelingsconsensus

By TipRanks

Strong Buy

9 ratings

Buy

Hold

Sell

Gebaseerd op 9 analisten die aandelenratings hebben gegeven aan Day One Biopharmaceuticals Inc - Dist in de afgelopen 3 maanden.

Technische score

By Trading Central

6.26 / 7.47Steun & Weerstand

Recent bearish events outweigh bullish events.

All events are bullish.

All events are bearish.

Sentiment

By Acuity

147 / 352 Rangschikking in Gezondheidszorg

Financieel

Verkoop- en administratiekosten

Bedrijfskosten

Winst voor belastingen

Verkoop

Kosten van verkopen

Brutowinst op verkopen

Rente-uitgaven op schulden

EBITDA

Operationele winst

Over Day One Biopharmaceuticals Inc

Day One Biopharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops and commercializes targeted therapies for patients with genomically defined cancers. Its lead product candidate is tovorafenib, an oral brain-penetrant type II pan-rapidly accelerated fibrosarcoma kinase inhibitor that is in Phase II clinical trial for pediatric patients with relapsed/ refractory low-grade glioma. The company is also developing Pimasertib, an oral small molecule inhibitor of mitogen-activated protein kinase kinases 1 and 2. Day One Biopharmaceuticals, Inc. was incorporated in 2018 and is headquartered in Brisbane, California.